The patients most likely to achieve remission have shorter diabetes duration, better preserved beta cell function, and achieve significant weight loss with treatment
How do dual agonists differ from single GLP-1 agonists
Individuals with metabolic syndrome features that span multiple domains (visceral obesity, insulin resistance, dyslipidemia) who want comprehensive metabolic intervention
Results from these clinical studies demonstrated significant improvements in glycaemic control, as indicated by notable reductions in glycated haemoglobin levels (-1.87% to -2.59%, -20 to -28 mmol/mol)
Campbell E, Takahashi Y, Abramovitz M, Peretz M, Listowsky I